Community
Company
News
Contact Us
Sign in

Please select the option that best describes you:

Topics: Gynecologic Cancers • Endometrial Cancer

If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?

Related Questions

Do you recommend a completion hysterectomy to patients who undergo primary radiation for endometrial cancer (presuming they are now a surgical candidate)?

Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?

How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?

Do you perform routine pelvic exams on patients undergoing active treatment for gynecologic cancer without GYN symptoms?

For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?

How do you manage a patient with widely metastatic serous endometrial cancer whose disease is stable after completion of 6 cycles of chemotherapy + immunotherapy?

What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?

Would you consider the addition of trabectedin to adjuvant doxorubicin in a patient with IVB leiomyosarcoma with completely resected disease (hysterectomy and thigh mass with negative margins)?

How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?

How would you manage a patient with FIGO 2018 IA G3 endometrioid adenocarcinoma with substantial LVSI, and was N- with adequate nodal staging?

Copyright © 2024 theMednet
All Rights Reserved.